Former FDA Commissioner Robert Califf, speaking at The Precision Medicine World Conference, discussed challenges facing the FDA, particularly under potential workforce reductions proposed by the Trump administration. He emphasized that losing personnel would inevitably lead to delays in product approvals, regardless of regulatory laws in place. Califf also defended FDA employees, asserting that they are dedicated professionals who are incorrectly represented as inefficient. His insights reflect broader concerns about the operational impacts of potential agency cuts on public health and regulatory efficacy.
To do the work, you actually have to pay people and they have to exist. So if enough people leave FDA, it doesn't matter what the law says, you're still going to have delays.
I think the people that are attracted [to the FDA] are very hardworking people and also have to say... the idea that federal employees are lazy or not as good as other employees is just flat out wrong.
Collection
[
|
...
]